SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Clostridium Difficile

tori avatar
tori
22 diapositives · 749 Views · Jul 27, 2014

Also known as c. diff. CDI CDAD Anna Alvarez 4/22/2010. Clostridium Difficile. C. difficille. gram + anaerobic bacillus found in the gut. flourishes when normal host microflora is inhibited by antibiotic use. Antibiotics mild to severe. Leading cause of infectious diarrhea in the U.S.

Clostridium Difficile - slide 1
01 / 22Clostridium Difficile
1 / 17

Télécharger la présentation

Clostridium Difficile
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. Also known as c. diff. • CDI • CDAD Anna Alvarez 4/22/2010 Clostridium Difficile

  2. C. difficille • gram + anaerobic bacillus found in the gut. • flourishes when normal host microflora is inhibited by antibiotic use. • Antibiotics • mild to severe

  3. Leading cause of infectious diarrhea in the U.S. • $ 2, 871 - $ 4, 846 – treatment of primary C diff. • $ 13, 655 - $18, 067- treatment of 1 recurring case of C diff. • Ghantoji, S.S., Sail,K., Lairson, DR. Dupont, HL, & Garey, K.W.( 2010) . Background

  4. Annual incidence- > 250, 000 nosocomial cases with a mortality rate of 1- 2.5%. • Annual cost of C diff in the US is between $750 million - $ 3.2 billion. • Elevated costs are due to multiple hospitalization and medications. • LOS 18.0 days vs. 4.0 ( CDI vs. Non CDI) • Ghantoji, S.S., Sail,K., Lairson, DR. Dupont, HL, & Garey, K.W.( 2010) . Background cont

  5. 10 day course of medication Metronidalizole = $26.42 Vancomycin = $ 863 - $1160 Ghantoji, S.S., Sail,K., Lairson, DR. Dupont, HL, & Garey, K.W.( 2010) Cost of Medication

  6. Multiple and prolonged antibiotic use penicillin, clindamycin, cephlasporins and fluoroquinolones( resistant form of C diff) • Immunocompromised- elderly, postop CV, DM, Renal disease, CA, HIV, transplant • Owens, R.C., Donskey,C.J.,Gaynes, R.P., Loo,V.G.& Muto,C., (2008). At risk POPUlations ( Common)

  7. Subjective history: foul smelling stools, greater than 3-6 watery stools within 24 hours. abdominal pain previous treatment with antibiotics dehydrated Kelly, C.P. & LaMont, T. ( 2008) Symptoms ( mild Case)

  8. Positive stool culture for toxin producing C diff. • Endoscopy: pseudomembranes noted, + toxin assay for toxin A/B . Diagnosis

  9. D/C triggering antibiotic • Rehydration with IV fluids • 10 day oral course of Vancomycin or Metrodianizole treatment

  10. Signs and symptoms of an acute abdomen abdominal pain, hypotension, elevated lactic acid, tachycardia, renal failure • Endoscopy: patches of pus sloughing , killing normal bowel. Severe Cases – pseudomembranaous colitis

  11. Pseudomembranous Colitis

  12. Toxic Megacolon • Medical emergency 32 – 80% mortality rate • Surgical intervention( exploratory laparotomy, subtotal colectomy, ileostomy) • Vancomycin and Metronidazole via N/G., or pr. • Al-Abed, Y.A., Gray, E.A. & Rothnie, N. D., (2010) Kelly, C.P. & LaMont, T. ( 2008)

  13. Virulent Strain (Kelly & Lamont,2008)

  14. Increased production of toxins A/B • Bind to colon tissue, release toxins • Responsible for major outbreaks • Recurrering infection • Kelly, C.P. & LaMont, T. ( 2008) North American Pulsed Field( NAP-1/027)

  15. Stool Transplantation • Family member • Stool screened for communicable diseases. Recipient treated with Vanco prior to the transplant • Stool was instilled via N/G tube and flushed with 25cc of NS. • No recurrence was noted. • Aas, C., Gessert, C. E., & Bakken, J., S. ( 2003). New Treatment!!

  16. Spore transmission through contact. • Spores live on object • Asymptomatic carriers of C diff spores. • Infection control measures • Bleach, isolation, disposable equipment, hand washing • Ghantoji, S.S., Sail,K., Lairson, DR. Dupont, HL, & Garey, K.W.( 2010) Community Acquired C Diff

  17. Pt/Family identify those at risk pt’s at risk for C diff/fulminating colitis encourage physicians to change to po meds as soon as possible teach pt / family – isolation, washing hands Role of the CNS

  18. Nurses • Adhere to appropriate isolation • Help nurses recognize those pt who are most at risk for further decline. CNS Role cont:

  19. Systems Monitor infection rates and collaborate with infection control , environmental. CNS ROLE CONT:

  20. Question

  21. Aas, J. Gessert, C.E., & Bakken, J.S. ( 2003) Recurrent Clostridium difficile colitis: Case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clinical Infectious Diseases, 36, 580-585. Al-Abed- Y.A., Gray, E.A. & Rothnie, N.D. (2010). Outcomes of emergency colectomy for fulminant Clostridium difficile colitis. The Surgeon, 330-333. Ghantoji, SS, Sail, K., Lairson, D.R., DuPont, H.L., & Garey, K.W.( 2010). Economic healthcare costs of Clostridium difficile infection: a systematic review. Journal of Hospital Infection, 74 309-318. Kelly, C. P., La Mont, T. ( 2008). Clostridium difficile- more difficult than ever. New England Journal of Medicine. 359, 1932- 1940. . References

  22. Owens, R.C., Donskey,C.J.,Gaynes, R.P., Loo,V.G.& Muto,C., (2008). Antimicrobial-associated risk factors for clostridium difficile infection. Clinical Infectious Disease, 46, S19- 2 31 References